Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biological Specimen Banks | 4 | 2022 | 75 | 1.110 |
Why?
|
| Retinoblastoma | 3 | 2012 | 189 | 0.710 |
Why?
|
| Biomedical Research | 3 | 2020 | 799 | 0.560 |
Why?
|
| Retinal Neoplasms | 2 | 2012 | 137 | 0.440 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 169 | 0.430 |
Why?
|
| Picornaviridae | 2 | 2013 | 20 | 0.410 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 143 | 0.400 |
Why?
|
| Glycoproteins | 1 | 2012 | 775 | 0.310 |
Why?
|
| Retina | 1 | 2012 | 550 | 0.310 |
Why?
|
| Antigens, CD | 1 | 2012 | 1420 | 0.280 |
Why?
|
| Peptides | 1 | 2012 | 1503 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2454 | 0.220 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 551 | 0.200 |
Why?
|
| Public Opinion | 1 | 2022 | 74 | 0.200 |
Why?
|
| Receptor, Notch4 | 1 | 2020 | 10 | 0.190 |
Why?
|
| Heart Septal Defects | 1 | 2020 | 48 | 0.180 |
Why?
|
| Genetic Therapy | 1 | 2007 | 1715 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 2347 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 239 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 165 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 526 | 0.150 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2022 | 253 | 0.150 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1796 | 0.150 |
Why?
|
| Down Syndrome | 1 | 2020 | 227 | 0.150 |
Why?
|
| Repressor Proteins | 2 | 2016 | 1716 | 0.140 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 1553 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 64 | 0.130 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 159 | 0.130 |
Why?
|
| RNA Splicing Factors | 1 | 2016 | 151 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 461 | 0.120 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 696 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 308 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 1581 | 0.110 |
Why?
|
| Proteomics | 1 | 2020 | 1425 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2016 | 610 | 0.110 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 53 | 0.100 |
Why?
|
| AC133 Antigen | 1 | 2012 | 107 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 128 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 2112 | 0.100 |
Why?
|
| Eye Proteins | 1 | 2012 | 279 | 0.090 |
Why?
|
| Phenotype | 1 | 2022 | 6502 | 0.090 |
Why?
|
| Genomics | 1 | 2020 | 2832 | 0.080 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 4968 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 251 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 7317 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6344 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 5759 | 0.070 |
Why?
|
| Stem Cells | 1 | 2014 | 1211 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2012 | 1723 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 284 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 1124 | 0.070 |
Why?
|
| Cystadenoma, Serous | 1 | 2005 | 31 | 0.060 |
Why?
|
| Hyaluronan Receptors | 1 | 2006 | 247 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3040 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 152 | 0.060 |
Why?
|
| Azetidines | 1 | 2006 | 95 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 108 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 493 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2010 | 570 | 0.060 |
Why?
|
| Mice | 6 | 2013 | 35421 | 0.060 |
Why?
|
| Humans | 18 | 2022 | 270713 | 0.060 |
Why?
|
| Child | 4 | 2020 | 30560 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 590 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 4202 | 0.060 |
Why?
|
| Phyllodes Tumor | 1 | 2004 | 64 | 0.060 |
Why?
|
| Myxoma | 1 | 2004 | 67 | 0.060 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2003 | 4 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2003 | 94 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 82 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2004 | 152 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2022 | 30 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1456 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2022 | 44 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 235 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5777 | 0.050 |
Why?
|
| Glioma | 1 | 2013 | 1986 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2004 | 253 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 372 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 1490 | 0.050 |
Why?
|
| Animals | 6 | 2013 | 61357 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 590 | 0.050 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 166 | 0.050 |
Why?
|
| Tetralogy of Fallot | 1 | 2022 | 163 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 239 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 3656 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 4054 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2005 | 1581 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 282 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 578 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 441 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 367 | 0.040 |
Why?
|
| Monocytes | 1 | 2022 | 784 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 186 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 560 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 1825 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 762 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 5332 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 866 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2022 | 721 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1930 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2022 | 1647 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 9463 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8603 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 796 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 734 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2014 | 153 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 34 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 3929 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 626 | 0.030 |
Why?
|
| Troponin T | 1 | 2014 | 257 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1648 | 0.020 |
Why?
|
| Cell Communication | 1 | 2014 | 509 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2007 | 33847 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 837 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 6881 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 4809 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1051 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2312 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1188 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 4248 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 5157 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 7920 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 10404 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2006 | 97 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 138 | 0.020 |
Why?
|
| Female | 6 | 2020 | 148885 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2005 | 210 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13994 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2010 | 3568 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3582 | 0.010 |
Why?
|
| Mastectomy, Simple | 1 | 2004 | 59 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2022 | 12042 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4644 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2003 | 58 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4104 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2003 | 49 | 0.010 |
Why?
|
| Omentum | 1 | 2004 | 109 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 245 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2004 | 257 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15828 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1307 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 346 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 9281 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1837 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 639 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2004 | 381 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 16244 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 1152 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 5313 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 4992 | 0.010 |
Why?
|
| Male | 2 | 2020 | 128479 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 2986 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 1931 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12530 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 7755 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 6193 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 7052 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 14878 | 0.010 |
Why?
|
| Adult | 3 | 2005 | 82041 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 7916 | 0.010 |
Why?
|
| Middle Aged | 2 | 2005 | 90533 | 0.000 |
Why?
|
| Mutation | 1 | 2006 | 15917 | 0.000 |
Why?
|
| Adolescent | 1 | 2005 | 32689 | 0.000 |
Why?
|